Declining obesity points to the wider accessibility of GLP-1 drugs, though researchers have said there are likely other factors as well
Patients cannot simply eat less of their usual dietthe quality, timing, and composition of meals require strategic adjustment to ensure adequate nutrition while minimizing gastrointestinal side effects
The results reported that HbA1c decreased in a dose-dependent manner with doses of 0.2-1.6 mg of semaglutide causing a significant decrease in HbA1c levels, in comparison to the placebo group
Market Size & Forecast (2024-2031), By Product, USD Million Ozempic Trulicity Mounjaro Wegovy Rybelsus Saxenda Others Market Size & Forecast (2024-2031), By Route of Administration, USD Million Subcutaneous Oral Market Size & Forecast (2024-2031), By Application, USD Million Diabetes Obesity Others Market Size & Forecast (2024-2031), By End-user, USD Million Hospitals Specialty Clinics Home-care Settings Others Market Size & Forecast (2024-2031), By Region, USD Million North America US Canada Europe UK Germany France Italy Spain Rest of Europe Asia Pacific China India Japan Rest of Asia Pacific Latin America Middle East & Africa Key Strategic Questions Addressed What is the market size & forecast of the GLP-1 analogues market